Although antibody technology has developed rapidly, antibody drugs are limited in their use because natural or recombinant unmodified antibodies are prone to cause an immune response in the body. PEG modification can overcome the short half-life of antibody fragments in blood circulation, reduce the cost of antibody fragments, and make them useful for clinical treatment.